For the Inventor, By the Inventor

Enter assignee name

Woodcliff Lake, NJ, United States of America

Eisai Inc.

USPTO Granted Patents = 33

% Expired Patents = 39.4

CIPO Patents = 10

EPO Patents = 14

Trademarks = 21

Forward Citations = 153

Loading Chart...

Loading Chart...

80 inventors (with patents filed for the assignee):

Jie Zhang (9 out of 37 patents)

Weizheng Xu (8 out of 14 patents)

Dana Victor Ferraris (7 out of 18 patents)

4. Gregory S Hamilton (6 out of 97 patents)

5. Bridget Duvall (6 out of 10 patents)

6. Greg Delahanty (6 out of 6 patents)

7. Nicholas C Nicolaides (5 out of 88 patents)

8. Luigi Grasso (4 out of 72 patents)

9. Mark Vaal (4 out of 6 patents)

10. Philip M Sass (4 out of 58 patents)

11. Sergei Belyakov (4 out of 5 patents)

12. Vincent Jacob Kalish (3 out of 52 patents)

13. Takashi Tsukamoto (3 out of 22 patents)

14. Jia-He Li (3 out of 44 patents)

15. Amy Xing (2 out of 10 patents)

Core Competencies:

Chlorotoxin Agents

Colorectal Cancer

Monoclonal Antibodies

PARP Inhibitors

Multikinase Inhibitors

Gastric Cancer

Hemiasterlin Derivatives

Thiolactones

CYP1B1 Nucleic Acids

Retinoid X Receptors

Diazabenzo Compounds

Phosphorus-Containing Compounds

33 patents: Sort by Forward Citations

1. 11826399 - Chlorotoxin agents and uses thereof (2023-11-28),

2. 10539565 - Methods for determining prognosis of colorectal cancer (2020-01-21),

3. 10509037 - Monoclonal antibodies that specifically block biological activity of a tumor antigen (2019-12-17),

4. 10364284 - High affinity antibodies that neutralizeenterotoxin B (2019-07-30),

5. 10253106 - Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells (2019-04-09),

6. 10221240 - Methods for treatment of gastric cancer (2019-03-05),

7. 10053509 - Methods for inhibiting the binding of endosialin to ligands (2018-08-21),

8. 8894989 - PARP inhibitor compounds, compositions and methods of use (2014-11-25),

9. 8883787 - Diazabenzo[de] anthracen-3-one compounds and methods for inhibiting PARP (2014-11-11),

10. 8618075 - Certain compounds, compositions and methods (2013-12-31),

11. 8609640 - Multikinase inhibitors for use in the treatment of cancer (2013-12-17),

12. 8609631 - Compositions and methods for treating cancer (2013-12-17),

13. 8470825 - Diazabenzo[de] anthracen-3-one compounds and methods for inhibiting PARP (2013-06-25),

14. 8329666 - Compositions and methods for treating cancer (2012-12-11),

15. 8329665 - Compositions and methods for treating cancer (2012-12-11),

Company Overview

Eisai Inc., headquartered in Woodcliff Lake, NJ, is a global pharmaceutical company dedicated to the research, development, and manufacturing of innovative medicines. The organization specializes in therapeutic areas such as neurology and oncology, focusing on addressing unmet medical needs through advanced drug discovery and development processes. With a commitment to improving patient outcomes, Eisai leverages cutting-edge technology and scientific expertise to deliver high-quality healthcare solutions worldwide.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

33 Patents

#3 in Woodcliff Lake, NJ

#408 in New Jersey

#10,305 in US

#20,147 in the World

Woodcliff Lake, NJ, United States of America

Eisai Inc.

Forward Citations = 153

80 inventors:

Jie Zhang (9 out of 37 patents)

Weizheng Xu (8 out of 14 patents)

Dana Victor Ferraris (7 out of 18 patents)

4. Gregory S Hamilton (6 out of 97 patents)

5. Bridget Duvall (6 out of 10 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Eisai Inc.. Retrieved from https://idiyas.com/company/eisai

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…